← Back to Search

Anti-VEGF

SCD411 for Age-Related Macular Degeneration

Phase 3
Waitlist Available
Research Sponsored by Sam Chun Dang Pharm. Co. Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks 4, 8, 20, 36 and 52
Awards & highlights

Study Summary

This study is evaluating whether a biosimilar to a drug used to treat wet age-related macular degeneration is as effective as the original drug.

Eligible Conditions
  • Age-Related Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks 4, 8, 20, 36 and 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, weeks 4, 8, 20, 36 and 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Change From Baseline in BCVA (Best Corrected Visual Acuity)
Percentage of Subjects With Anti-SCD411 Antibodies

Side effects data

From 2022 Phase 3 trial • 576 Patients • NCT04480463
7%
COVID-19
5%
Neovascular age-related macular degeneration
4%
Visual acuity reduced
3%
Back pain
2%
Urinary tract infection
2%
Arthralgia
1%
Age-related macular degeneration
1%
Angina pectoris
1%
Blepharitis
1%
Pain in extremity
1%
Gastritis
1%
Inguinal hernia
1%
Nausea
1%
Diarrhoea
1%
Intraocular pressure increased
1%
Ocular hypertension
1%
Retinal haemorrhage
1%
Punctate keratitis
1%
Hypertension
1%
Dizziness
1%
Corneal erosion
1%
Osteoporosis
1%
Vitreous floaters
1%
Headache
1%
Tinnitus
1%
Vitreous detachment
1%
Eye pain
1%
Vomiting
1%
Conjunctivitis
1%
Dry eye
1%
Cataract
100%
80%
60%
40%
20%
0%
Study treatment Arm
Aflibercept
SCD411

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: SCD411Experimental Treatment1 Intervention
Group II: AfliberceptActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SCD411
2020
Completed Phase 3
~580

Find a Location

Who is running the clinical trial?

Sam Chun Dang Pharm. Co. Ltd.Lead Sponsor
Byung Jhip HaStudy DirectorSam Chun Dang Pharm. Co. Ltd.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
2020. "A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04480463.
~123 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top